Cancer Research Technology
Owkin, NanoString Technologies Launch $50M Spatial Omics Research Program for Cancer Research
The companies have assembled a coalition of research institutions in the US and Europe to apply spatial omics to biomarker and drug discovery.
The firm has revamped its business model to focus on AI-driven drug discovery and partnerships with pharma and academic cancer researchers.
New Company Achilles Therapeutics Formed to Advance Personalized Immunotherapies
The new firm, created by Syncona and Cancer Research Technology, has raised $17.5 million to support development of individualized therapies targeted to tumor neoantigens.
IP Watch: Biomérieux, BD, Fluidigm, Cancer Research Technology, and Gen-Probe Win US Patents
Premium
Biomérieux has been awarded US Patent No. 8,106,172, "Nucleic acid sequences that can be used as primers and probes in the amplification and detection of SARS coronavirus."
In its companion diagnostics development program for an investigational PARP inhibitor oncologic, Pfizer is pursuing methylation-specific biomarkers rather than BRCA gene mutations to help personalize the drug.
Jan 31, 2011
MDxHealth Partners on Biomarker for PARP Inhibitor
Jun 10, 2009